Skip Navigation LinksHome > August 2012 - Volume 34 - Issue 6 > Effect of Recombinant Human Growth Hormone (rhGH) on Hemoglo...
Text sizing:
A
A
A
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e318253f082
Original Articles

Effect of Recombinant Human Growth Hormone (rhGH) on Hemoglobin Concentration in Children With Idiopathic Growth Hormone Deficiency-related Anemia

Miniero, Roberto MD*; Altomare, Federica MD*; Rubino, Mario MD*; Matarazzo, Patrizia MD; Montanari, Claudio MD; Petri, Antonella MD§; Raiola, Giuseppe MD; Bona, Gianni MD§

Collapse Box

Abstract

Normocytic-normochromic anemia (NC/NC) has been attributed to impaired bone marrow erythropoiesis in growth hormone (GH)-deficient patients. Moreover, the GH/insulin-like growth factor-1 (IGF-1) axis has been implicated in erythropoiesis regulation. In this retrospective multicenter study, we evaluated the incidence of NC/NC anemia in 279 children (196 boys), median age 10.52 years, with isolated idiopathic GH deficiency, and the effect of recombinant human growth hormone (rhGH) therapy on hemoglobin levels. At 6-month intervals, we recorded the Hb standard deviation score (Hb-SDS), the IGF-1-SDS, weight, height, and pubertal stage. Forty-one boys and 7 girls had NC/NC anemia before starting substitutive therapy (−2.59 SD). The Hb-SDS was significantly increased (P<0.05) after 12 months of rhGH therapy. The effect of rhGH continued up to 48 months (−0.39 SD), at which point all children had normal hemoglobin values. In conclusion, rhGH therapy resulted in normal hemoglobin values in all children enrolled in the study. These data support the concept that the GH/IGF-1 axis promotes erythropoiesis in vivo.

© 2012 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/JPHOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.